Norway Savings Bank Boosts Holdings in Johnson & Johnson (NYSE:JNJ)

Norway Savings Bank lifted its stake in Johnson & Johnson (NYSE:JNJ) by 1.4% in the 3rd quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission. The firm owned 18,154 shares of the company’s stock after purchasing an additional 250 shares during the period. Johnson & Johnson accounts for about 1.4% of Norway Savings Bank’s investment portfolio, making the stock its 17th biggest holding. Norway Savings Bank’s holdings in Johnson & Johnson were worth $2,932,000 as of its most recent filing with the Securities and Exchange Commission.

Several other large investors also recently bought and sold shares of the company. Vanguard Group Inc. lifted its position in shares of Johnson & Johnson by 0.7% in the 2nd quarter. Vanguard Group Inc. now owns 231,432,368 shares of the company’s stock worth $38,126,168,000 after purchasing an additional 1,701,721 shares during the period. BlackRock Inc. lifted its position in shares of Johnson & Johnson by 0.9% in the 2nd quarter. BlackRock Inc. now owns 191,385,110 shares of the company’s stock worth $31,528,781,000 after purchasing an additional 1,694,112 shares during the period. State Street Corp lifted its position in shares of Johnson & Johnson by 1.3% in the 2nd quarter. State Street Corp now owns 142,047,884 shares of the company’s stock worth $23,400,968,000 after purchasing an additional 1,777,289 shares during the period. Geode Capital Management LLC lifted its position in shares of Johnson & Johnson by 3.4% in the 2nd quarter. Geode Capital Management LLC now owns 42,214,232 shares of the company’s stock worth $6,934,570,000 after purchasing an additional 1,388,991 shares during the period. Finally, Bank of New York Mellon Corp lifted its position in Johnson & Johnson by 3.3% during the 2nd quarter. Bank of New York Mellon Corp now owns 32,881,689 shares of the company’s stock valued at $5,416,930,000 after acquiring an additional 1,042,663 shares during the period. 67.14% of the stock is owned by hedge funds and other institutional investors.

JNJ opened at $160.24 on Thursday. The company has a current ratio of 1.34, a quick ratio of 1.11 and a debt-to-equity ratio of 0.43. The company has a market cap of $421.85 billion, a price-to-earnings ratio of 23.95, a PEG ratio of 2.38 and a beta of 0.71. The company’s 50 day moving average is $162.64 and its 200 day moving average is $167.35. Johnson & Johnson has a 12-month low of $142.86 and a 12-month high of $179.92.

Johnson & Johnson (NYSE:JNJ) last posted its quarterly earnings data on Monday, October 18th. The company reported $2.60 earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of $2.35 by $0.25. The company had revenue of $23.34 billion for the quarter, compared to the consensus estimate of $23.72 billion. Johnson & Johnson had a net margin of 19.55% and a return on equity of 37.90%. The firm’s revenue was up 10.7% compared to the same quarter last year. During the same quarter last year, the firm posted $2.20 earnings per share. As a group, analysts predict that Johnson & Johnson will post 9.78 EPS for the current fiscal year.

The firm also recently disclosed a quarterly dividend, which will be paid on Tuesday, December 7th. Investors of record on Tuesday, November 23rd will be issued a $1.06 dividend. This represents a $4.24 dividend on an annualized basis and a dividend yield of 2.65%. The ex-dividend date is Monday, November 22nd. Johnson & Johnson’s payout ratio is 63.38%.

A number of research analysts recently issued reports on JNJ shares. Raymond James lowered their price target on shares of Johnson & Johnson from $183.00 to $178.00 and set an “outperform” rating for the company in a research report on Wednesday, October 20th. SVB Leerink reissued a “buy” rating on shares of Johnson & Johnson in a research report on Thursday, July 29th. Zacks Investment Research raised shares of Johnson & Johnson from a “hold” rating to a “buy” rating and set a $172.00 price target for the company in a research report on Friday, October 22nd. Morgan Stanley lowered shares of Johnson & Johnson from an “overweight” rating to an “equal weight” rating and set a $187.00 price objective for the company. in a research note on Tuesday, September 7th. Finally, Wells Fargo & Company restated a “buy” rating on shares of Johnson & Johnson in a research note on Thursday, October 7th. Two investment analysts have rated the stock with a hold rating and seven have given a buy rating to the stock. According to data from MarketBeat.com, the company has a consensus rating of “Buy” and a consensus price target of $187.78.

About Johnson & Johnson

Johnson & Johnson is a holding company, which engages in the research and development, manufacture and sale of products in the health care field. It operates through the following segments: Consumer Health, Pharmaceutical, and Medical Devices. The Consumer Health segment includes products used in the baby care, oral care, beauty, over-the-counter pharmaceutical, women’s health, and wound care markets.

Recommended Story: Upside/Downside Explanation

Want to see what other hedge funds are holding JNJ? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Johnson & Johnson (NYSE:JNJ).

Institutional Ownership by Quarter for Johnson & Johnson (NYSE:JNJ)

Receive News & Ratings for Johnson & Johnson Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Johnson & Johnson and related companies with MarketBeat.com's FREE daily email newsletter.